Our site may be slower due to heavy traffic from automated "bots" and AI crawlers. We're working to fix this.

Sarah M Larson

Title(s)HS Associate Clinical Professor, Medicine
SchoolMedicine
Emailslarson@mednet.ucla.edu
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025. J Natl Compr Canc Netw. 2025 05; 23(5):132-140. Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Baz R, Campagnaro E, Costello C, D'Angelo C, Derman B, Devarakonda S, Elsedawy N, Godara A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee HC, Liedtke M, Martin T, Omel J, Robinson T, Rosenberg A, Schroeder MA, Sherbenou D, Suvannasankha A, Valent J, Varshavsky-Yanovsky AN, Vogl D, Kovach E, Kumar R. PMID: 40340857.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    2. A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome. Ann Hematol. 2025 Mar; 104(3):1577-1585. Garcia-Manero G, Gaddh M, Platzbecker U, Lindsley RC, Larson SM, Chevassut T, Fenaux P, Komrokji R, Lyons R, Al-Kali A, Jiang Y, Bothos J, Townsley DM, Zeidan AM. PMID: 40153010; PMCID: PMC12031784.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    3. Allogeneic chimeric antigen receptors (CARs) as an "off-the-shelf" therapy in multiple myeloma. Immunotherapy. 2025 02; 17(3):211-222. Carlson S, Lin TL, Larson SM. PMID: 39961649; PMCID: PMC11951714.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    4. Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study. Blood. 2025 01 16; 145(3):300-310. Badros A, Foster L, Anderson LD, Chaulagain CP, Pettijohn E, Cowan AJ, Costello C, Larson S, Sborov DW, Shain KH, Silbermann R, Shah N, Chung A, Krevvata M, Pei H, Patel S, Khare V, Cortoos A, Carson R, Lin TS, Voorhees P. PMID: 39331724; PMCID: PMC11775507.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    5. The Impact of Social Determinants of Health on Peripheral T Cell Lymphoma Outcomes: Treatment Center-Type Emerges as a Powerful Prognostic Indicator. Clin Lymphoma Myeloma Leuk. 2025 Mar; 25(3):162-177. Mead M, Glenn B, Tuscano J, Saha A, Larson S, Carlson S, Zain J. PMID: 39477702.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method. Nat Biotechnol. 2025 Mar; 43(3):329-344. Li YR, Zhou Y, Yu J, Kim YJ, Li M, Lee D, Zhou K, Chen Y, Zhu Y, Wang YC, Li Z, Yu Y, Dunn ZS, Guo W, Cen X, Husman T, Bajpai A, Kramer A, Wilson M, Fang Y, Huang J, Li S, Zhou Y, Zhang Y, Hahn Z, Zhu E, Ma F, Pan C, Lusis AJ, Zhou JJ, Seet CS, Kohn DB, Wang P, Zhou XJ, Pellegrini M, Puliafito BR, Larson SM, Yang L. PMID: 38744947; PMCID: PMC11919731.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    7. Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy. Mol Ther. 2024 Jun 05; 32(6):1849-1874. Li YR, Zhou Y, Yu J, Zhu Y, Lee D, Zhu E, Li Z, Kim YJ, Zhou K, Fang Y, Lyu Z, Chen Y, Tian Y, Huang J, Cen X, Husman T, Cho JM, Hsiai T, Zhou JJ, Wang P, Puliafito BR, Larson SM, Yang L. PMID: 38584391; PMCID: PMC11184334.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    8. Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024 01; 22(1D):e240001. Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Baz R, Campagnaro E, Castillo JJ, Costello C, D'Angelo C, Derman B, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee H, Liedtke M, Martin T, Omel J, Robinson T, Rosenberg A, Sborov D, Schroeder MA, Sherbenou D, Suvannasankha A, Valent J, Varshavsky-Yanovsky AN, Snedeker J, Kumar R. PMID: 38244272.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    9. Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 12; 21(12):1281-1301. Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Baz R, Campagnaro E, Castillo JJ, Costello C, D'Angelo C, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee HC, Liedtke M, Martin T, Omel J, Robinson T, Rosenberg A, Sborov D, Schroeder MA, Sherbenou D, Suvannasankha A, Valent J, Varshavsky-Yanovsky AN, Kumar R, Snedeker J. PMID: 38081133.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    10. Regional sex differences in neurochemical profiles of healthy mice measured by magnetic resonance spectroscopy at 9.4 tesla. Front Neurosci. 2023; 17:1278828. Tkác I, Xie T, Shah N, Larson S, Dubinsky JM, Gomez-Pastor R, McLoughlin HS, Orr HT, Eberly LE, Öz G. PMID: 37954878; PMCID: PMC10634209.
      View in: PubMed   Mentions: 4  
    11. Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE. Br J Haematol. 2023 09; 202(5):942-952. Shah NP, García-Gutiérrez V, Jiménez-Velasco A, Larson SM, Saussele S, Rea D, Mahon FX, Levy MY, Gómez-Casares MT, Mauro MJ, Sy O, Martin-Regueira P, Lipton JH. PMID: 37246588; PMCID: PMC10524617.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    12. Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. Nat Med. 2023 04; 29(4):869-879. Crees ZD, Rettig MP, Jayasinghe RG, Stockerl-Goldstein K, Larson SM, Arpad I, Milone GA, Martino M, Stiff P, Sborov D, Pereira D, Micallef I, Moreno-Jiménez G, Mikala G, Coronel MLP, Holtick U, Hiemenz J, Qazilbash MH, Hardy N, Latif T, García-Cadenas I, Vainstein-Haras A, Sorani E, Gliko-Kabir I, Goldstein I, Ickowicz D, Shemesh-Darvish L, Kadosh S, Gao F, Schroeder MA, Vij R, DiPersio JF. PMID: 37069359; PMCID: PMC10115633.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCellsCTClinical Trials
    13. CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma. Cancer Discov. 2023 03 01; 13(3):580-597. Larson SM, Walthers CM, Ji B, Ghafouri SN, Naparstek J, Trent J, Chen JM, Roshandell M, Harris C, Khericha M, Schweppe T, Berent-Maoz B, Gosliner SB, Almaktari A, Ceja MA, Allen-Auerbach MS, Said J, Nawaly K, Mead M, de Vos S, Young PA, Oliai C, Schiller GJ, Timmerman JM, Ribas A, Chen YY. PMID: 36416874; PMCID: PMC9992104.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCells
    14. Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 01; 21(1):67-81. Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Campagnaro E, Castillo JJ, Costello C, D'Angelo C, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee HC, Liedtke M, Martin T, Omel J, Rosenberg A, Sborov D, Valent J, Berardi R, Kumar R. PMID: 36652935.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    15. A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013. NPJ Breast Cancer. 2022 Dec 30; 8(1):134. Ademuyiwa FO, Gao F, Street CR, Chen I, Northfelt DW, Wesolowski R, Arora M, Brufsky A, Dees EC, Santa-Maria CA, Connolly RM, Force J, Moreno-Aspitia A, Herndon JM, Carmody M, Davies SR, Larson S, Pfaff KL, Jones SM, Weirather JL, Giobbie-Hurder A, Rodig SJ, Liu Z, Hagemann IS, Sharon E, Gillanders WE. PMID: 36585404; PMCID: PMC9803651.
      View in: PubMed   Mentions: 26  
    16. Impact of comorbidity in older patients with peripheral T-cell lymphoma: an international retrospective analysis of 891 patients. Blood Adv. 2022 04 12; 6(7):2120-2128. Mead M, Cederleuf H, Björklund M, Wang X, Relander T, Jerkeman M, Gaut D, Larson S, Ellin F. PMID: 34570186; PMCID: PMC9006283.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    17. Moving Toward a Cure for Myeloma. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-12. Mateos MV, Nooka AK, Larson SM. PMID: 35623025.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    18. NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022. J Natl Compr Canc Netw. 2022 01; 20(1):8-19. Callander NS, Baljevic M, Adekola K, Anderson LD, Campagnaro E, Castillo JJ, Costello C, Devarakonda S, Elsedawy N, Faiman M, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Liedtke M, Martin T, Omel J, Sborov D, Shain K, Stockerl-Goldstein K, Weber D, Berardi RA, Kumar R, Kumar SK. PMID: 34991075.
      View in: PubMed   Mentions: 96     Fields:    Translation:Humans
    19. Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy. Cell Rep Med. 2021 11 16; 2(11):100449. Li YR, Zhou Y, Kim YJ, Zhu Y, Ma F, Yu J, Wang YC, Chen X, Li Z, Zeng S, Wang X, Lee D, Ku J, Tsao T, Hardoy C, Huang J, Cheng D, Montel-Hagen A, Seet CS, Crooks GM, Larson SM, Sasine JP, Wang X, Pellegrini M, Ribas A, Kohn DB, Witte O, Wang P, Yang L. PMID: 34841295; PMCID: PMC8607011.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansAnimalsCells
    20. Real-World Experience of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Aggressive B-cell Lymphomas: A Single-Institution Experience. Clin Lymphoma Myeloma Leuk. 2021 12; 21(12):861-872. Ghafouri S, Fenerty K, Schiller G, de Vos S, Eradat H, Timmerman J, Larson S, Mead M. PMID: 34389271.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    21. A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma. Am J Cancer Res. 2021; 11(6):3285-3293. Cornell RF, Bishop MR, Kumar S, Giralt SA, Nooka AK, Larson SM, Locke FL, Raje NS, Lei L, Dong J, Le Gall JB, Rossi JM, Orlowski RZ. PMID: 34249462; PMCID: PMC8263642.
      View in: PubMed   Mentions: 9  
    22. Cost-Health Literacy as an Educational Objective in Fellowship Training. J Cancer Educ. 2022 10; 37(5):1479-1485. Fischer KA, Anand S, Walling A, Larson SM, Glaspy J. PMID: 33761118.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    23. 'Tracking Together'-Simultaneous Use of Human and Dog Activity Trackers: Protocol for a Factorial, Randomized Controlled Pilot Trial. Int J Environ Res Public Health. 2021 02 07; 18(4). Jayawardene W, Huber L, McDonnell J, Curran L, Larson S, Dickinson S, Chen X, Pena E, Carson A, Johnston J. PMID: 33562180; PMCID: PMC7916073.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCTClinical Trials
    24. Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 12 02; 18(12):1685-1717. Kumar SK, Callander NS, Adekola K, Anderson L, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Kang Y, Hultcrantz M, Larson S, Liedtke M, Martin T, Omel J, Shain K, Sborov D, Stockerl-Goldstein K, Weber D, Keller J, Kumar R. PMID: 33285522.
      View in: PubMed   Mentions: 114     Fields:    Translation:HumansCells
    25. Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies? Bone Marrow Transplant. 2021 04; 56(4):974-977. Ghafouri S, Timmerman J, Larson S, Mead MD. PMID: 33168933; PMCID: PMC8035067.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    26. A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors. Cancer Chemother Pharmacol. 2021 03; 87(3):337-347. Park H, Williams K, Trikalinos NA, Larson S, Tan B, Waqar S, Suresh R, Morgensztern D, Van Tine BA, Govindan R, Luo J, Lockhart AC, Wang-Gillam A. PMID: 33159216; PMCID: PMC8454489.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    27. Nivolumab Treatment of Burkitt Lymphoma: A Case Report. Ann Intern Med. 2021 04; 174(4):567-568. Colton BS, Hornstein N, Timmerman J, Larson S, Glaspy J. PMID: 33105097.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    28. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leuk Lymphoma. 2020 03; 61(3):650-659. Shah NP, García-Gutiérrez V, Jiménez-Velasco A, Larson S, Saussele S, Rea D, Mahon FX, Levy MY, Gómez-Casares MT, Pane F, Nicolini FE, Mauro MJ, Sy O, Martin-Regueira P, Lipton JH. PMID: 31647335.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansCTClinical Trials
    29. Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer. Cell Stem Cell. 2019 10 03; 25(4):542-557.e9. Zhu Y, Smith DJ, Zhou Y, Li YR, Yu J, Lee D, Wang YC, Di Biase S, Wang X, Hardoy C, Ku J, Tsao T, Lin LJ, Pham AT, Moon H, McLaughlin J, Cheng D, Hollis RP, Campo-Fernandez B, Urbinati F, Wei L, Pang L, Rezek V, Berent-Maoz B, Macabali MH, Gjertson D, Wang X, Galic Z, Kitchen SG, An DS, Hu-Lieskovan S, Kaplan-Lefko PJ, De Oliveira SN, Seet CS, Larson SM, Forman SJ, Heath JR, Zack JA, Crooks GM, Radu CG, Ribas A, Kohn DB, Witte ON, Yang L. PMID: 31495780; PMCID: PMC7018522.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansAnimalsCells
    30. An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1-HK2+ Multiple Myeloma. Cancer Res. 2019 05 15; 79(10):2748-2760. Xu S, Zhou T, Doh HM, Trinh KR, Catapang A, Lee JT, Braas D, Bayley NA, Yamada RE, Vasuthasawat A, Sasine JP, Timmerman JM, Larson SM, Kim Y, MacLeod AR, Morrison SL, Herschman HR. PMID: 30885978; PMCID: PMC6522331.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    31. Antisense oligonucleotide-mediated ataxin-1 reduction prolongs survival in SCA1 mice and reveals disease-associated transcriptome profiles. JCI Insight. 2018 11 02; 3(21). Friedrich J, Kordasiewicz HB, O'Callaghan B, Handler HP, Wagener C, Duvick L, Swayze EE, Rainwater O, Hofstra B, Benneyworth M, Nichols-Meade T, Yang P, Chen Z, Ortiz JP, Clark HB, Öz G, Larson S, Zoghbi HY, Henzler C, Orr HT. PMID: 30385727; PMCID: PMC6238731.
      View in: PubMed   Mentions: 82     Fields:    Translation:AnimalsCells
    32. Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. Leuk Lymphoma. 2018 11; 59(11):2588-2594. Chari A, Larson S, Holkova B, Cornell RF, Gasparetto C, Karanes C, Matous JV, Niesvizky R, Valent J, Lunning M, Usmani SZ, Anderson LD, Chang L, Lee Y, Pak Y, Salman Z, Graef T, Bilotti E, Chhabra S. PMID: 29616843.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    33. Pre-clinical development of gene modification of haematopoietic stem cells with chimeric antigen receptors for cancer immunotherapy. Hum Vaccin Immunother. 2017 05 04; 13(5):1094-1104. Larson SM, Truscott LC, Chiou TT, Patel A, Kao R, Tu A, Tyagi T, Lu X, Elashoff D, De Oliveira SN. PMID: 28059624; PMCID: PMC5443385.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    34. Gene-modified hematopoietic stem cells for cancer immunotherapy. Hum Vaccin Immunother. 2014; 10(4):982-5. Larson S, De Oliveira SN. PMID: 24398603; PMCID: PMC4896508.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    35. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leuk Lymphoma. 2012 Mar; 53(3):445-50. Larson SM, Campbell NP, Huo D, Artz A, Zhang Y, Gajria D, Green M, Weiner H, Daugherty C, Odenike O, Godley LA, Hyjek E, Gurbuxani S, Thirman M, Sipkins D, Van Besien K, Larson RA, Stock W. PMID: 21913806.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    36. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood. 2011 Nov 10; 118(19):5119-25. Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, Fenske TS, Hurd DD, Goy A, Schneider SE, Keppel CR, Wagner-Johnston ND, Carson KR, Bartlett NL. PMID: 21937701; PMCID: PMC3217400.
      View in: PubMed   Mentions: 76     Fields:    Translation:HumansCellsCTClinical Trials
    Sarah's Networks
    Concepts (151)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (35)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-16-gff1bd585 on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California